Share

Tasly Pharmaceutical Group Co., Ltd Stocks

CN¥ 13.87Last Updated 13.04.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 3.03B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 13.87
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Tasly Pharmaceutical Group Co., Ltd. engages in biological medicine, health, and medical service businesses in China. It offers herbal and chemical medicines, health products, pharmaceutical substances and APIs, herbal extracts, concentrated herbal granules, and tea series products. The company also provides cosmetic series products, including moisture lotions, moisture creams, eye creams, and face washing foams; daily hygiene products, such as sanitary and carefree pads, honey-propolis soaps, and pollen soaps; and medical equipment, which include massage tappers, massage cushions, and circulation machines. It also exports its products to the United States, Russia, and countries in Europe, Africa, and rest of Asia. Tasly Pharmaceutical Group Co., Ltd. was founded in 1994 and is based in Tianjin, China.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks